申请人:Chiesi Farmaceutici S.p.A.
公开号:US07838534B2
公开(公告)日:2010-11-23
Quinuclidine derivative of the general formula (I) in the form of single enantiomers or mixtures thereof are useful in the manufacture of a medicament for the prevention and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema
wherein:
R1 is selected from H, F, Cl, Br, I and (C1-C4)-alkyl;
R2 is optionally substituted 2- or 3-thienyl, or substituted phenyl;
R3 is (CH2)1-4—COR4 or (CH2)1-4—S(O)nR4, wherein R4 is optionally substituted phenyl or optionally substituted 2- or 3-thienyl;
n is 0, 1 or 2;
X− is a pharmaceutically acceptable anion.
通式(I)的喹诺啡啶衍生物以单一对映体或其混合物的形式,用于制造用于预防和治疗呼吸疾病,如哮喘、慢性阻塞性肺疾病(COPD)、慢性支气管炎、咳嗽和肺气肿的药物,其中:R1选自H、F、Cl、Br、I和(C1-C4)-烷基;R2是可选取的2-或3-噻吩基或取代的苯基;R3是(CH2)1-4-COR4或(CH2)1-4-S(O)nR4,其中R4是可选取的取代苯基或取代的2-或3-噻吩基;n为0、1或2;X-是一种药学上可接受的阴离子。